Pharmaceutical packaging occupies a critical position in the product lifecycle. From both a regulatory and quality control perspective, it is a critical component of the finished medicinal product. Errors in labelling, content information, 1D/2D codes, or Braille embossing can trigger product recalls and, in severe cases, directly endanger patient safety. Incorrect codes can also compromise traceability systems for medications throughout the supply chain, with significant downstream implications for pharmacovigilance and serialisation compliance.

Against this backdrop, automated print inspection systems have become the established standard in modern pharmaceutical packaging, replacing time-consuming and error-prone manual visual inspection. These systems deliver standardised, reproducible inspection results and are capable of simultaneously assessing print image integrity, code legibility and grading, and Braille embossing compliance in a single pass. Beyond efficiency gains, they generate comprehensive, audit-proof inspection reports. The inspection data accumulated by these systems represents a largely underutilised asset that, when systematically consolidated and analysed, can yield significant insights into process quality, recurring defects, and systemic risks.

Regulatory Framework

Any use of automated inspection data within a pharmaceutical quality context must be grounded in the applicable regulatory framework. Two primary regulatory instruments define the requirements for computer-based inspection systems and their data outputs:

In Europe, EU GMP Annex 11 and Annex 15 are most directly applicable. Annex 15 requires that quality-critical systems and processes be formally qualified (for systems) and validated (for processes), with supporting documentation maintained on a risk-based basis. Packaging quality characteristics must be reproducibly present and systematically tested. Annex 11 governs computer-based systems, including complete and consistent data recording, traceability, protection against unauthorised access or alteration, regular data backup, and the maintenance of an audit trail. Inspection decisions and batch release actions must be documented in an auditproof manner. Inspection reports, typically stored as PDF files immediately upon test completion, satisfy these requirements by default, though digital backup of extensive reports is advisable.

In the United States, 21 CFR Part 11 (in effect since 1997) sets out the equivalence of electronic records and signatures with their paper-based counterparts. Key requirements applicable to inspection systems include system validation (§11.10(a)), access controls (§11.10(d)), audit trails (§11.10(e)), sequential use of test steps and status indicators (§11.10(f)), and documented user training and qualification (§11.10(i)). A significant regulatory gap is identified: neither Annex 11 nor 21 CFR Part 11 explicitly addresses the procedures for retrospective analysis or secondary use of inspection data. This gap represents both a limitation and an opportunity, as there is substantial analytical potential between regulatory minimum requirements and datadriven quality assurance.